Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database

BACKGROUND: Smoothened (SMO) inhibitors, blocking the sonic hedgehog pathway, have been approved for advanced basal cell carcinoma (aBCC). Safety analyses reveal a high rate of adverse events (AEs) and, most of the time, vismodegib is most commonly stopped when the best overall response is reached....

Descripción completa

Detalles Bibliográficos
Autores principales: Bassompierre, A., Dalac, S., Dreno, B., Neidhardt, E.M., Maubec, E., Capelle, C., Andre, F., Behal, H., Dziwniel, V., Bens, G., Leccia, M.T., Meyer, N., Granel-Brocard, F., Beylot-Barry, M., Dereure, O., Basset-Seguin, N., Mortier, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551849/
https://www.ncbi.nlm.nih.gov/pubmed/34689002
http://dx.doi.org/10.1016/j.esmoop.2021.100284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551849/
https://www.ncbi.nlm.nih.gov/pubmed/34689002
http://dx.doi.org/10.1016/j.esmoop.2021.100284

Ejemplares similares